WO2002017961A1 - Preparation d'un vaccin renfermant un acide gras comme compose - Google Patents
Preparation d'un vaccin renfermant un acide gras comme compose Download PDFInfo
- Publication number
- WO2002017961A1 WO2002017961A1 PCT/JP2001/007379 JP0107379W WO0217961A1 WO 2002017961 A1 WO2002017961 A1 WO 2002017961A1 JP 0107379 W JP0107379 W JP 0107379W WO 0217961 A1 WO0217961 A1 WO 0217961A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fatty acid
- component
- preparation containing
- vaccine preparation
- containing fatty
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0015—Combination vaccines based on measles-mumps-rubella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36211—Rubivirus, e.g. rubella virus
- C12N2770/36234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/363,484 US7560484B2 (en) | 2000-08-31 | 2001-08-28 | Vaccine preparation containing fatty acid as a constituent |
AU2001280208A AU2001280208A1 (en) | 2000-08-31 | 2001-08-28 | Vaccine preparation containing fatty acid as component |
EP01958570A EP1316314A4 (en) | 2000-08-31 | 2001-08-28 | PREPARATION OF A VACCINE CONTAINING FATTY ACID AS A COMPOUND |
CA002420601A CA2420601A1 (en) | 2000-08-31 | 2001-08-28 | Vaccine preparation containing fatty acid as component |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000268390 | 2000-08-31 | ||
JP2000-268390 | 2000-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002017961A1 true WO2002017961A1 (fr) | 2002-03-07 |
Family
ID=18755175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/007379 WO2002017961A1 (fr) | 2000-08-31 | 2001-08-28 | Preparation d'un vaccin renfermant un acide gras comme compose |
Country Status (6)
Country | Link |
---|---|
US (1) | US7560484B2 (ja) |
EP (1) | EP1316314A4 (ja) |
AU (1) | AU2001280208A1 (ja) |
CA (1) | CA2420601A1 (ja) |
TW (1) | TWI247607B (ja) |
WO (1) | WO2002017961A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1601375A2 (en) * | 2003-03-12 | 2005-12-07 | Wyeth | Adjuvanted bovine vaccines |
WO2008093772A1 (ja) * | 2007-01-31 | 2008-08-07 | Hisamitsu Pharmaceutical Co., Inc. | 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤 |
WO2018074327A1 (ja) * | 2016-10-20 | 2018-04-26 | 株式会社山田養蜂場本社 | 粘膜免疫調節剤 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4046708B2 (ja) * | 2004-06-04 | 2008-02-13 | 明治製菓株式会社 | 3−アルケニルセフェム化合物の製造方法 |
WO2007015441A1 (ja) | 2005-08-01 | 2007-02-08 | Hisamitsu Pharmaceutical Co., Inc. | 経皮または経粘膜投与のためのアジュバントおよび製剤 |
CN102176907A (zh) * | 2008-10-08 | 2011-09-07 | 免疫解决方案有限公司 | 用于产生粘膜免疫的口服疫苗 |
WO2011081488A2 (ko) * | 2009-12-30 | 2011-07-07 | Lee Hai Soo | 밀겨 추출물 또는 이로부터 분리한 유효물질을 이용한 비만 개선제 조성물 |
EP3064218B1 (en) | 2013-10-31 | 2019-06-19 | Hisamitsu Pharmaceutical Co., Inc. | Adjuvant composition |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH059130A (ja) * | 1990-09-21 | 1993-01-19 | Takeda Chem Ind Ltd | イムノグロブリン含有ワクチン製剤 |
JPH07173069A (ja) * | 1993-12-17 | 1995-07-11 | Tsumura & Co | アジュバント作用剤 |
WO1996006627A1 (en) * | 1994-08-26 | 1996-03-07 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
WO1996032964A1 (fr) * | 1995-04-20 | 1996-10-24 | Societe D'exploitation De Produits Pour Les Industries Chimiques-Seppic | Composition therapeutique comprenant un antigene ou un generateur in vivo d'un compose comprenant une sequence d'acides amines |
WO2000051634A1 (fr) * | 1999-03-03 | 2000-09-08 | The Kitasato Institute | Preparations de vaccins contenant des acides gras comme composants |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW586935B (en) | 1998-09-14 | 2004-05-11 | Kitasato Inst | Saponin-containing vaccine preparation |
BR9915533A (pt) | 1998-10-21 | 2001-11-06 | Kitasato Inst | Preparações de vacina contendo toxina atenuada |
-
2001
- 2001-08-28 US US10/363,484 patent/US7560484B2/en not_active Expired - Fee Related
- 2001-08-28 WO PCT/JP2001/007379 patent/WO2002017961A1/ja not_active Application Discontinuation
- 2001-08-28 EP EP01958570A patent/EP1316314A4/en not_active Withdrawn
- 2001-08-28 CA CA002420601A patent/CA2420601A1/en not_active Abandoned
- 2001-08-28 AU AU2001280208A patent/AU2001280208A1/en not_active Abandoned
- 2001-08-29 TW TW090121273A patent/TWI247607B/zh not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH059130A (ja) * | 1990-09-21 | 1993-01-19 | Takeda Chem Ind Ltd | イムノグロブリン含有ワクチン製剤 |
JPH07173069A (ja) * | 1993-12-17 | 1995-07-11 | Tsumura & Co | アジュバント作用剤 |
WO1996006627A1 (en) * | 1994-08-26 | 1996-03-07 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
WO1996032964A1 (fr) * | 1995-04-20 | 1996-10-24 | Societe D'exploitation De Produits Pour Les Industries Chimiques-Seppic | Composition therapeutique comprenant un antigene ou un generateur in vivo d'un compose comprenant une sequence d'acides amines |
WO2000051634A1 (fr) * | 1999-03-03 | 2000-09-08 | The Kitasato Institute | Preparations de vaccins contenant des acides gras comme composants |
Non-Patent Citations (3)
Title |
---|
MARUNO M.: "Research for active principles of Pinelliae Tuber and new preparation of crude drugs", JOURNAL OF TRADITIONAL MEDICINES, vol. 14, 1997, pages 81 - 88, XP002949741 * |
See also references of EP1316314A4 * |
YAMADA H. ET AL.: "In vivo antiinfluenza virus activity of Kampo medicine Sho-seiryu-to through mucosal immune system", METH. FIND. EXP. CLIN. PHARMACOL., vol. 20, no. 3, April 1998 (1998-04-01), pages 185 - 192, XP002949740 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1601375A2 (en) * | 2003-03-12 | 2005-12-07 | Wyeth | Adjuvanted bovine vaccines |
WO2008093772A1 (ja) * | 2007-01-31 | 2008-08-07 | Hisamitsu Pharmaceutical Co., Inc. | 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤 |
JP5275047B2 (ja) * | 2007-01-31 | 2013-08-28 | 久光製薬株式会社 | 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤 |
WO2018074327A1 (ja) * | 2016-10-20 | 2018-04-26 | 株式会社山田養蜂場本社 | 粘膜免疫調節剤 |
US11089805B2 (en) | 2016-10-20 | 2021-08-17 | Yamada Bee Company, Inc. | Mucosal immunomodulator |
Also Published As
Publication number | Publication date |
---|---|
CA2420601A1 (en) | 2003-02-26 |
US7560484B2 (en) | 2009-07-14 |
TWI247607B (en) | 2006-01-21 |
AU2001280208A1 (en) | 2002-03-13 |
US20040024058A1 (en) | 2004-02-05 |
EP1316314A1 (en) | 2003-06-04 |
EP1316314A4 (en) | 2004-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002013857A3 (en) | A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof | |
WO2000007621A3 (en) | Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent | |
EP1955709A3 (en) | Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines | |
WO2002009746A8 (en) | Vaccines comprising outer membrane vesciles from gram negative bacteria | |
WO2002046189A3 (en) | Aryl ether substituted imidazoquinolines | |
HK1051650A1 (en) | Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response. | |
WO2004075829A3 (en) | Adjuvanted influenza vaccine | |
WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
CA2237529A1 (en) | Vaccine compositions for intranasal administration comprising chitosan and use thereof | |
WO2004030608A3 (en) | Nanoemulsion vaccines | |
WO2001076370A3 (en) | Anthelmintic combinations | |
WO2002028427A3 (fr) | Composition pharmaceutique pour l'immunisation contre le sida | |
WO2001068129A3 (de) | Adjuvans für vakzinen | |
WO2001000232A3 (en) | Use of cpg as an adjuvant for hiv vaccine | |
AU2001271963A1 (en) | Mid-life vaccine and methods for boosting anti-mycobacterial immunity | |
EP1152051A3 (de) | Wässrige Reinigungsmittel | |
WO2003041735A3 (en) | Composotion comprising inhibitors of the notch signalling pathway for the modulation of the immune system | |
WO2002017961A1 (fr) | Preparation d'un vaccin renfermant un acide gras comme compose | |
WO2003059385A3 (en) | Hiv vaccine and method of use | |
GB9422990D0 (en) | Immunogenic compositions | |
HK1047034A1 (zh) | Cpg作為瘧疾疫苗佐劑的用途 | |
WO2001070265A3 (en) | Lipopeptide adjuvants | |
WO2002022150A3 (de) | Arzneimittel enthaltend aktiviertes antithrombin iii | |
WO2002000208A3 (de) | Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen | |
AU2001278680A1 (en) | Erectile dysfunction remedies containing prostaglandin derivatives as the activeingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BE DE FR GB IT |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002522934 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2420601 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001280208 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001958570 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001958570 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10363484 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001958570 Country of ref document: EP |